Alnylam Pharmaceuticals said this week that the US Patent and Trademark Office has allowed a patent application covering compositions and methods for siRNAs.

The application, No. 20070275465, is entitled, "Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism." According to Alnylam, claims in the application include a dsRNA of any length having effectiveness in inhibiting a target gene via RNAi; overhang or blunt-end design features; and a 19 to 28 nucleotide region of the antisense strand that is complementary to a target gene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.